NCT06626555View on ClinicalTrials.gov

Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

HIV

Interventions

DRUG

Letermovir

Letermovir 480mg PO once daily

All Listed Sponsors

collaborator

Royal Free Hospital NHS Foundation Trust

OTHER

lead

University College, London

OTHER